These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22564052)

  • 41. Salmon calcitonin-loaded Eudragit® and Eudragit®-PLGA nanoparticles: in vitro and in vivo evaluation.
    Cetin M; Aktas MS; Vural I; Ozturk M
    J Microencapsul; 2012; 29(2):156-66. PubMed ID: 22126314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stability of a transdermal salmon calcitonin formulation.
    Chang SL; Hofmann GA; Zhang L; Deftos LJ; Banga AK
    Drug Deliv; 2003; 10(1):41-5. PubMed ID: 12554363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts.
    Song KH; Chung SJ; Shim CK
    J Control Release; 2005 Sep; 106(3):298-308. PubMed ID: 15979756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy.
    Youn YS; Jung JY; Oh SH; Yoo SD; Lee KC
    J Control Release; 2006 Sep; 114(3):334-42. PubMed ID: 16884808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of proteolytic enzyme inhibitors as absorption enhancers on the transdermal iontophoretic delivery of calcitonin in rats.
    Morimoto K; Iwakura Y; Nakatani E; Miyazaki M; Tojima H
    J Pharm Pharmacol; 1992 Mar; 44(3):216-8. PubMed ID: 1354726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transdermal absorption enhancement of papain loaded in elastic niosomes incorporated in gel for scar treatment.
    Manosroi A; Chankhampan C; Manosroi W; Manosroi J
    Eur J Pharm Sci; 2013 Feb; 48(3):474-83. PubMed ID: 23266464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regional oral absorption, hepatic first-pass effect, and non-linear disposition of salmon calcitonin in beagle dogs.
    Hee Lee Y; Leesman GD; Makhey V; Yu H; Hu P; Perry B; Sutyak JP; Wagner EJ; Falzone LM; Stern W; Sinko PJ
    Eur J Pharm Biopharm; 2000 Sep; 50(2):205-11. PubMed ID: 10962228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin.
    Morimoto K; Katsumata H; Yabuta T; Iwanaga K; Kakemi M; Tabata Y; Ikada Y
    Eur J Pharm Sci; 2001 May; 13(2):179-85. PubMed ID: 11297902
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Chemical stability of salmon calcitonin (sCT) analogues in aqueous solution].
    Yang B; Cai Y; Han Z; Wu L; Ding Z; Zhang Q; Yang S
    Yao Xue Xue Bao; 1998 Aug; 33(8):610-5. PubMed ID: 12016902
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Formulation and evaluation of lidocaine base ethosomes for transdermal delivery.
    Zhu X; Li F; Peng X; Zeng K
    Anesth Analg; 2013 Aug; 117(2):352-7. PubMed ID: 23744957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats.
    Katsumi H; Liu S; Tanaka Y; Hitomi K; Hayashi R; Hirai Y; Kusamori K; Quan YS; Kamiyama F; Sakane T; Yamamoto A
    J Pharm Sci; 2012 Sep; 101(9):3230-8. PubMed ID: 22467424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin.
    Sang Yoo H; Gwan Park T
    J Pharm Sci; 2004 Feb; 93(2):488-95. PubMed ID: 14705204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium.
    Manosroi A; Jantrawut P; Manosroi J
    Int J Pharm; 2008 Aug; 360(1-2):156-63. PubMed ID: 18539416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug reservoir composition and transport of salmon calcitonin in transdermal iontophoresis.
    Santi P; Colombo P; Bettini R; Catellani PL; Minutello A; Volpato NM
    Pharm Res; 1997 Jan; 14(1):63-6. PubMed ID: 9034222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of reversible and nonreversible aqueous-soluble lipidized conjugates of salmon calcitonin.
    Cheng W; Lim LY
    Mol Pharm; 2008; 5(4):610-21. PubMed ID: 18481870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Examination of Effective Buccal Absorption of Salmon Calcitonin Using Cell-Penetrating Peptide-Conjugated Liposomal Drug Delivery System.
    Keum T; Noh G; Seo JE; Bashyal S; Sohn DH; Lee S
    Int J Nanomedicine; 2022; 17():697-710. PubMed ID: 35210769
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transdermal iontophoretic delivery of salmon calcitonin.
    Chang SL; Hofmann GA; Zhang L; Deftos LJ; Banga AK
    Int J Pharm; 2000 Apr; 200(1):107-13. PubMed ID: 10845691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin.
    Sakuma S; Suzuki N; Sudo R; Hiwatari K; Kishida A; Akashi M
    Int J Pharm; 2002 Jun; 239(1-2):185-95. PubMed ID: 12052704
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced transbuccal salmon calcitonin (sCT) delivery: effect of chemical enhancers and electrical assistance on in vitro sCT buccal permeation.
    Oh DH; Chun KH; Jeon SO; Kang JW; Lee S
    Eur J Pharm Biopharm; 2011 Oct; 79(2):357-63. PubMed ID: 21683790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol.
    Shin BS; Jung JH; Lee KC; Yoo SD
    Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):957-60. PubMed ID: 15304989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.